Posaconazole for the treatment of oropharyngeal candidiasis, including triazole-resistant disease, in HIV-positive patients

Oropharyngeal candidiasis is a common affliction in HIV-positive patients worldwide. Although the incidence has decreased with the advent of potent antiviral combinations, it continues to be a cause of significant morbidity. Historically, fluconazole or itraconazole was the treatment of choice for oropharyngeal candidiasis, but increasing incidence of resistance and high recurrence rates mandate the use of alternative therapies. Posaconazole, a broad-spectrum second-generation triazole antifungal agent, has been studied in both first-line and salvage settings for treatment of oropharyngeal candidiasis. Posaconazole is well-tolerated, yields high response rates and demonstrates durable response rates with long-term use. This review will provide state-of-the-art knowledge of pharmacology and therapeutics of posaconazole focusing on the indication for oropharyngeal candidiasis in HIV-positive patients.

• Population(s)
  • General HIV+ population
• Co-infections
  • Other